TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: unfavourable DS-TB outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSD during pregnancy or postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripartum depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total seizure burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: haemostasis points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prevalence of visual impairment (PVA, WHO definition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with postoperative analgesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in daily activities and social participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: IBS-Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge about vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year IFFS
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of TAO-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in AH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects (hyperpigmentation and erythema)
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal LN count according to two-category classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: illusion of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wrist’s extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality by 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Functional status at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Assessment (PtGA) score of 0/1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ≥ 4-point improvement in Night Time Itch Scale (NTIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in Patient-Oriented Eczema Measure (POEM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Relative Difference (ARD) in glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIV (Peripheral Inflammatory Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: median decrease in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median catheterization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: preservation of erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reading fluency (words per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) in Trendelenburg position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in atrophic scar acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nurses' degree of satisfaction with the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated blood loss during myomectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-assessed moderate or severe asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Technical issues during consultations
Endpoint domain: Adverse events/effects
Primary endpoint: Median etonogestrel concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median ethinyl estradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of IL-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first pre-syncopal episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically-verified smoking abstinence rates
Endpoint domain: Mortality/survival
Primary endpoint: MBO resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrografin passage to rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of fatty liver (LA < 40 HU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dyspepsia symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Breast appearance improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete cessation of epileptic spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median motor scores by DASII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median mental scores by DASII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin/Glucagon (INS/GCN) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: scar cosmesis assessment and rating scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to undergo lung cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postpartum visits attended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: P. falciparum SCP clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Withdrawal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight-gain velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of weight/length disproportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worst pain experienced over the past week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simultaneous improvement in ACR 50 and PASI 100 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCI‐CTCAE neuropathy grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ntx‐12 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum levels of BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month 'slip' defined as exceeding a blood alcohol concentration of 0.05%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Schizophrenia (SCZ)
Endpoint domain: Mortality/survival
Primary endpoint: Fluoride reactivity with enamel and dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of early readmissions after COVID-related hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: blood sugar control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difficulty swallowing
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue severity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to identify ISP (TISP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygenation (PaO2 values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Office visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of hospitalization or death through day 29
Endpoint domain: Mortality/survival
Primary endpoint: implant insertion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of responders in task activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically meaningful weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra- and postoperative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density at five years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorbability at the osteotomy site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation at the osteotomy site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendation adherence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant-reported benefit from participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: materialism
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum 24,25(OH)2D3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum 3-epi-25(OH)D3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in range 70-140 (TIR70–140)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in hypoglycaemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent elevated depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of detectable TFV‐DP at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP use throughout follow‐up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mental Component Scale (MCS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability improvement (Roland Morris Disability Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color change of denture teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with HIV-1 RNA level ≥50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observer-rated PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality delivery of palliative care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: risk of low attained power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life Years (LYs)
Endpoint domain: Resource use
Primary endpoint: complete remission rate of cervical lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean predicted postoperative refraction (PPOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in critical thinking self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tricuspid annular plane systolic excursion (TAPSE) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular global longitudinal strain (LVGLS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular global longitudinal strain (RVGLS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FMA-distal (hand/wrist units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMA-total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonintensification of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower intentions to engage with hookah tobacco ads
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Greater negative emotional response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satisfaction with transitional care services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daily fruit consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dollars spent at the targeted store
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chest wall expansion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: penile size development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testicular volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hormonal levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Participant accrual rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs of recruitment methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postoperative IIEF-EF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual penile curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nicotine exposure (AUC0–60-BL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work-related injury and disease prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burnout prevalence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Bone mineral density (BMD) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day composite of recurrent venous thrombo-embolism, major bleeding or all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: rate of patients discharged home within 24 hours after randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: V̇O2peak estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain level (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of PORT initiation delay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average total annual cost of providing HIV care and treatment per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average provider cost per patient retained in care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decline in cytokine production capacity for tumor necrosis factor α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decline in cytokine production capacity for interleukin‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urgency at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fecal incontinence-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: UvPO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Death or dependency at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Poor primary efficacy outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT/GOG‐Taxane score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patients’ pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: good stroke outcome (modified Rankin Scale score 0-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain during the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Financial cost of the OFA protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RTI simple reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retraction speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment preferences
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of patients achieving HbA1c < 7% without weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nipple pain prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nipple trauma prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory muscle strength (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity level (IPAQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional exercise capacity (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal symptom scores for rhinitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS of axial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 1-h postprandial glucose (PPG) increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of treatment-emergent severe or BG-confirmed hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: New York Heart Association classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Color Doppler echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain injury scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Temporal demand
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BAT fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Confidence in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: favorable functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: First-pass success rate of guided endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of glaucoma after cataract removal
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of glaucoma plus glaucoma suspect diagnosis after cataract removal
Endpoint domain: Adverse events/effects
Primary endpoint: Referral for follow-up colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation between SpHb and LabHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bias of SpHb compared to LabHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion decision change rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Event rate of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Event rate of transient elevated alanine aminotransferase/aspartate aminotransferase TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: lesion-based accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔPes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 count below 350 cells/μL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hemorrhoids rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodal recurrence after radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Restitution of UVFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in balance and functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain activation during response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes